Lang W, Wang J, Ouyang M, Zhao H, et al. Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China. PLoS One 2025;20:e0331338.
PMID: 41004550